Acevedo Christopher P. 4

What Happened

• Christopher P. Acevedo, Chief Financial Officer of OS Therapies Inc. (OSTX), was granted options to acquire 100,000 shares of the company's common stock on January 22, 2026. The filing lists these as a derivative award with an acquisition price of $0.00 per share (total cash outlay shown $0). This is a compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: January 22, 2026 (reported on Form 4 filed February 13, 2026).
• Grant size: options to acquire 100,000 shares; price shown in filing: $0.00 per share (derivative securities).
• Vesting: options vest in full on the one-year anniversary of the grant, provided Acevedo remains employed on that date (footnote in filing).
• Shares owned after the reported transaction: not specified in the provided filing details.
• Filing timeliness: Form 4 was filed ~3 weeks after the transaction (Form 4s are generally due within two business days), so this filing appears late.

Context

• This was an award of options (a right to buy shares in the future if/when vested and exercised), not an immediate purchase of common stock. The filing does not show any immediate exercise or sale tied to this grant.
• Awards like this are commonly used for executive compensation; they are routine but do not necessarily indicate a direct bullish or bearish signal from an insider.